SPL

2.11%

9.3¢ starpharma holdings limited

Really your looking back to 2015 for negative stuff to post most...

First 18 Last

Share
Profile

Follow
thrasher

4,870 Posts.

259

01/10/22

11:25

Post #: 63979287
Share

Originally posted by sarge17: ↑

Dr Behrenbruch got some pushback after his frank assessment of Starpharma. This was his reply:

As a number of (slightly cocky and goading) readers pointed out today, my prior post on Starpharma's utterly stupid pre-clinical announcement had a major flaw. In the interest of being comprehensive, I would like to make an additional follow-up comment, while completely acknowledging my own incompetence and stupidity.I was too busy telling you about the gaps in Starpharma's underwhelming mouse study. I was so busy reacting with ridicule that in climbing over itself to make a completely sensationalist but irrelevant ASX announcement, Starpharma didn't actually bother finishing the animals studies (still ongoing, apparently). I was so busy trying to recalibrate you on the lack of controls and the basic lack of meaningful information, that I forgot something super important.What is that you may ask?Well, the super-important information that I didn't see - but that several other people did - was the lack of efficacy in the Herceptin (naked antibody) and Kadcyla (ADC) comparative treatment arms. Duh. Below is a figure from a nice paper in Clinical Cancer Research from 2011 that shows the type of response we expect to see in a SKOV-3 model with Herceptin. I should note that the Herceptin (Trastuzumab) tumour response is very typical, per the references in this 2011 paper.So yes, the message you should take home is not only was Starphama's basic scientific integrity poor, and not only was the data incomplete, but the actual data itself is crap. I should also add that not only is it surprising that the company shows basically nil treatment effect in a xenograft model that is well known to respond well to Herceptin (and Kadycla), but also no dose is disclosed for the comparative treatment arms, nor any data on animal weight loss (to calibrate tumour volume changes). Both of which would be de rigeur …Sloppy, sloppy, sloppy.

Expand

Really your looking back to 2015 for negative stuff to post most posters here would have entered after that myself 2016, for heavens sake what has the Starpharma of 2015 got to do with the Starpharma of 2022, starting to get a bit concerned at where your going with this obsession sarge it's getting silly.

SPL Price at posting: 62.5¢ Sentiment: Hold Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

Is oil undervalued?

NXG

Cost blow-out for Rook I uranium project sees share plummet for NexGen

VMS

Venture to sniff out high-grade REE targets at Jupiter project, WA

VMT

Vmoto sales plummet -50% YoY as weak demand in Europe & China stifles EV scooter sales growth

DVP

Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place

GRX

GreenX picks up prospective copper project in Germany

WGX

Westgold sets its sights on top five producer status through merger with Karora

Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo

BOE

Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan

MGU

Collaboration in a green (steel) future the focus for Magnum and Saudi partners

There are more pages in this discussion • 3 more messages in this thread...

First 18 Last

Add SPL (ASX) to my watchlist

(20min delay)
Last 9.3¢		Change -0.002(2.11%)		Mkt cap ! $38.35M

Open	High	Low	Value	Volume
9.5¢	9.5¢	9.3¢	$48.64K	512.2K

Buyers (Bids)

No.	Vol.	Price($)
3	153365	9.3¢

Sellers (Offers)

Price($)	Vol.	No.
9.8¢	65000	1

View Market Depth

No.	Vol.	Price($)
3	153365	0.093
1	60000	0.092
1	5000	0.090
1	50000	0.089
2	147200	0.087

Price($)	Vol.	No.
0.098	65000	1
0.099	56700	2
0.100	111205	3
0.105	146531	5
0.110	43099	6

Last trade - 16.10pm 02/08/2024 (20 minute delay)

SPL (ASX) Chart

Really your looking back to 2015 for negative stuff to post most...

Is oil undervalued?

Cost blow-out for Rook I uranium project sees share plummet for NexGen

Venture to sniff out high-grade REE targets at Jupiter project, WA

Vmoto sales plummet -50% YoY as weak demand in Europe & China stifles EV scooter sales growth

Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place

GreenX picks up prospective copper project in Germany

Westgold sets its sights on top five producer status through merger with Karora

Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo

Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan

Collaboration in a green (steel) future the focus for Magnum and Saudi partners

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Really your looking back to 2015 for negative stuff to post most...

Top Stories

Is oil undervalued?

Cost blow-out for Rook I uranium project sees share plummet for NexGen

Venture to sniff out high-grade REE targets at Jupiter project, WA

Vmoto sales plummet -50% YoY as weak demand in Europe & China stifles EV scooter sales growth

Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place

GreenX picks up prospective copper project in Germany

Westgold sets its sights on top five producer status through merger with Karora

Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo

Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan

Collaboration in a green (steel) future the focus for Magnum and Saudi partners

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News